Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.

Human molecular genetics - 15 Apr 2010

Riessland Markus, Ackermann Bastian, Förster Anja, Jakubik Miriam, Hauke Jan, Garbes Lutz, Fritzsche Ina, Mende Ylva, Blumcke Ingmar, Hahnen Eric, Wirth Brunhilde

Abstract excerpt

Proximal spinal muscular atrophy (SMA) is a common autosomal recessively inherited neuromuscular disorder determined by functional impairment of alpha-motor neurons within the spinal cord. SMA is caused by functional loss of the survival motor neuron gene 1 (SMN1), whereas disease severity is mainly influenced by the number of SMN2 copies. SMN2, which produces only low levels of full-length mRNA/protein, can be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hydroxamic Acids
Share to Italy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Transgenic

Share to Motor Activity

Share to Muscular Atrophy, Spinal

Share to Survival of Motor Neuron 1 Protein

Share to Survival of Motor Neuron 2 Protein

Share to Vorinostat

Source

Identifiers

PMID: 20097677
DOI: 10.1093/hmg/ddq023

Genes

SMN2
SMN1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.PMID 20097677Read ↗

Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585.Semantic proximity Read ↗

An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular AtrophySemantic proximity Read ↗

<i>In vitro</i> and <i>ex vivo</i> evaluation of second‐generation histone deacetylase inhibitors for the treatment of spinal muscular atrophySemantic proximity Read ↗

Spinal muscular atrophy: mechanisms and therapeutic strategies.Semantic proximity Read ↗

Spinal muscular atrophy and therapeutic prospects.Semantic proximity Read ↗

Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy TherapySemantic proximity Read ↗

SMN-Inducing Compounds For The Treatment Of Spinal Muscular AtrophySemantic proximity Read ↗

LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproateSemantic proximity Read ↗

Spinal muscular atrophy: a timely review.Semantic proximity Read ↗

Combining SMN2 splicing modifiers with HDAC6 inhibition greatly improves muscle function and survival in Spinal Muscular AtrophySemantic proximity Read ↗

Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent LandscapeSemantic proximity Read ↗

Combined treatment with the histone deacetylase inhibitor LBH589 and a splice‐switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.